MPH MITTELSTAENDISCHE PHARMA HOLDING AG September 3, 2014
MPH Mittelständische Pharma Holding AG: Information on the issuance of new shares in connection with the capital increase from company funds and the conversion of preference shares into ordinary shares - trading under new WKN and ISIN
The Annual General Shareholders' Meeting from June 27, 2014 has resolved, inter alia, to increase the share capital of the company from company funds while issuing one new share on 25 existing shares. Furthermore, the conversion of the preference shares without voting rights into ordinary shares with voting rights was passed.
The capital increase from company funds was implemented by converting a portion of the amount of capital and revenue reserves, amounting to
5,928,071.20 Euro as of December 31, 2013. Company's share capital was
increased from corporate funds by 1,646,687.00 Euro from 41,167,155.00
Euro to 42,813,842.00 Euro. The capital increase was implemented by the issue of 1,646,687 new, no-par bearer shares, to the shareholder in a ratio of
25:1, meaning that one new bearer share will be allocated additionally for
every twenty five existing shares.
In addition, the company announces the implementation of the resolution of the Annual General Shareholders' Meeting and of the separate meeting of preference share holders on the conversion of the preference shares without voting rights into ordinary shares with voting rights by cancelling the preference rights of the preference shares. Thereby, the preference shares were merged with the ordinary shares. All shares are publicly traded under WKN A0L1H3 (ISIN: DE000A0L1H32) with immediate effect. Concerning this matter, the company points out that orders relating the preference shares have been deleted and have to be replaced.
In accordance to the resolutions, the Articles of the Association and the global certificate have been adjusted in the meantime.
The capital increase from company funds and the conversion of the preference shares into ordinary shares as well as the respective amendments in the Articles of Association were entered in the commercial register on July 10,
2014 and thereby became effective.
Due to the company's success the Management Board of the company has decided to propose the issuance of new shares through a capital increase from company funds to enable shareholders the participation in this success.
MPH Mittelständische Pharma Holding AG Linda Reichelt
Fasanenstraße 77 | Phone.: +49 (0)30 897 30 86 60 | E-Mail: ir@mph-ag.de |
D-10623 Berlin | Fax: +49 (0)30 897 30 86 69 | Web: www.mph-ag.de |
September 3, 2014
About MPH Mittelständische Pharma Holding AG:
The company MPH Mittelständische Pharma Holding AG, based in Berlin, has strategically concentrated its activities on the growth segments of the healthcare market and is aimed to make a contribution towards cutting costs in the healthcare system.
The focus lies on medicines manufactured on the basis of patent-free and patent-protected active substances for the therapy of chronic diseases. Complementary, services for individual patient therapies, aesthetic surgeries and other medical treatments are offered along the value-added-chain in the healthcare market.
MPH Mittelständische Pharma Holding AG is listed in the Entry Standard (Open
Market) of the Frankfurt stock exchange.
Key figures for the share of MPH Mittelständische Pharma Holding AG: Subscribed capital: EUR 42,813,842.00.
ISIN: DE000A0L1H32
WKN: A0L1H3
MPH Mittelständische Pharma Holding AG Linda Reichelt
Fasanenstraße 77 Phone.: +49 (0)30 897 30 86 60 E-Mail: ir@mph-ag.de
D-10623 Berlin Fax: +49 (0)30 897 30 86 69 Web: www.mph-ag.de
|
distributed by
|
